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Adrenocorticotrophic hormone lowers serum Lp(a) and LDL choles-
terol concentrations in hemodialysis patients. Previously, we have shown
that short-term administration of adrenocorticotrophic hormone (ACTH)
results in reduced concentrations of apolipoprotein B-containing lipopro-
teins, including lipoprotein(a), and reduced activities of hepatic lipase.
These effects were observed in steroid-treated patients suffering from
iatrogenic ACTH deficiency and in healthy individuals. The direct nature
of the influence of ACTH on hepatic lipoprotein metabolism was con-
firmed by in vitro experiments. The aim of the present investigation was to
study the effects of ACTH treatment on uremic patients, who exhibit
disturbed lipoprotein pattern due to the slow removal of triglyceride-rich
lipoproteins and who probably are ACTH resistant. Eight patients on
chronic hemodialysis were studied. After one intramuscular injection of
Synacthen Depot (a synthetic ACTH1.24 preparation from Ciba Geigy
AG, Basel, Switzerland) 1 mg, the only change noted was a significant
reduction of 26% in median lipoprotein(a) concentration. After five
injections, a further decrease (65%) was found in the lipoprotein(a)
concentration. Also, reductions in median concentrations of total choles-
terol, low density lipoprotein cholesterol and apolipoprotein B were
observed. The magnitude of these changes was 15 to 30%. In contrast to
previously studied groups, no changes were observed regarding triglycer-
ide metabolism. Significantly increased median concentration of apoli-
poprotein CIII was found. However, the excess apolipoprotein CIII was
confined to the fraction that was not associated with apolipoprotein B.
Thus, administration of ACTH to uremic patients improved their athero-
genie lipoprotein profile, a fact that may have future therapeutic implica-
tions. In comparison to previously studied groups, the uremic patients
responded rather slowly and not at all regarding triglyceride metabolism.
The lipoprotein pattern of uremia is well known [1, 2]. The
main features include moderate hypertriglyceridemia, low high
density lipoprotein (HDL) cholesterol concentration, and accu-
mulation of remnant particles [3]. In general, the apolipoprotein
composition agrees with the lipid profile [4]. This lipoprotein
pattern is in accordance with delayed catabolism of triglyceride-
Key words: uremia, lipoprotein, hypertriglyceridemia, acrenocorticotro-
phic hormone, triglycerides, hemodialysis.
Received for publication March 5, 1997
and in revised form July 17, 1997
Accepted for publication July 30, 1997
© 1997 by the International Society of Nephrology
rich lipoproteins [5], probably caused by reduced activity of
lipoprotein lipase (LPL) in combination with disturbed enzyme
substrate and possibly receptor ligand functions of the lipopro-
teins [5—7]. However, although the general outlines of the patho-
genetic process seem clear, there is still a lot to be learned. In spite
of the atherogenic features observed in a population at greatly
increased risk of death in the complications of atherosclerosis [8],
there is as yet no consensus on an appropriate lipid-lowering
treatment.
It has recently been shown that, in addition to the classical
dyslipoproteinemic features, lipoprotein(a) [Lp(a)] concentration
is increased in hemodialysis patients who manifest high molecular
weight isotypes of apolipoprotein(a) [9]. The mechanism behind
this phenomenon is not known. Increased concentration of Ii-
poprotein(a) is a well established, independent risk factor for the
development of atherosclerosis [10], but to date there is no safe
and effective treatment, neither in uremia nor in general.
Recently, we reported a lipid-lowering effect of short-term
adrenocorticotrophic hormone (ACTH) treatment in healthy
individuals [111 as well as in steroid-treated patients [12]. In both
groups, total cholesterol and triglyceride concentrations fell mark-
edly, suggesting an enhanced uptake of apolipoprotein B-contain-
ing lipoproteins via the low density lipoprotein (LDL) receptor.
Moreover, HL activity was decreased after ACTH treatment, a
finding that could explain the observed increase in HDL2 choles-
terol concentration. The hypothesis that ACTH exerts direct
effects on hepatic lipoprotein metabolism was supported by in
vitro experiments with HepG2 cells (a human hepatoma cell line)
[11] (Berg et al, unpublished observations). The administration of
ACTH also resulted in a decrease in Lp(a) concentration [11, 121.
However, Lp(a) concentration responded similarly to dexameth-
asone treatment, indicating that this otherwise unexplained effect
is at least partly steroid-mediated [11]. The increase in LPL
activity after ACTH treatment, observed only in the steroid-
treated group of patients [121, suggested the involvement of
extrahepatic tissues. The aim of the present study was to find out
whether ACTH exerts its lipid-lowering effect also on uremic
patients, in spite of their complicated disturbances of lipoprotein
metabolism and possible ACTH resistance [13, 14]. This was done
with future treatment possibilities in mind as well as the hope of
gaining additional insights into this recently recognized effect of
ACTH and into the uremic dyslipoproteinemia.
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Table I. Serum lipid, lipoprotein and apolipoprotein concentrations as well as postheparin plasma lipase activities in hemodialysis patients
Day 1 Day 3 Day 8 Day 22
Serum total cholesterol mmol/liter 5.34 (4.04—7.89) 5.31 (4.07—7.25) 4.66 (3.66_6.88)° 5.24 (4.07—7.36)
Serum HDL cholesterol mmol/liter 0.65 (0.56—1.65) 0.72 (0.56—1.54) 0.70 (0.52—1.54) 0.69 (0.56—1.50)
Serum LDL cholesterol mmol/liter 3.67 (2.60—5.89) 3.70 (2.34—5.44) 2.55 (2.02_5.01)a 3.70 (2.63—5.55)
LDL/HDL 5.3 (3.1—6.8) 4.9 (3.5—6.4) 3.4 (2.9—6.3) 5.0 (3.6—8.1)
Serum triglycerides mmol/liter 1.71 (0.78—4.20) 1.69 (0.61—3.24) 2.10 (0.73—5.43) 1.53 (0.69—2.89)
Serum apo Al g/liter 1.06 (0.96—1.51) 1.07 (0.96—1.52) 1.11 (0.94—1.47) 1.06 (1.00—1.49)
Serum apo B g/liter 1.14 (0.94—1.37) 1.10 (0.92—1.31) 0.93 (0.73_l.20)a 1.15 (0.88—1.63)
Serum apo B-associated apo CIII mg/titer 20(7—26) 15 (3—24) 22(10—27) 14 (7—39)
Serum nonapo B-associated apo CIII mg/liter 31(18—85) 31(19—84) 48 (23—120)° 25 (13—84)
Serum apo B-associated apo E mg/liter 15 (11—20) 12 (4—30) 17(9—120) 16 (9—60)
Serum nonapo B-associated apo E mg/liter 35 (15—220) 39 (26—230) 38 (17—300) 37(19—300)
Serum lipoprotein(a) mg/liter 167 (82—703) 122 (52_626)° 41 (16—399)° 187 (72— 826)
Plasma lipoprotein lipase mU/mi 38 (17—87) 47 (28—105) 34 (13—71) 40 (18—79)
Plasma hepatic lipase mU/mi 147 (57—427) 117 (54—444) 117 (52—342) 136 (64—278)
Day 1, baseline; day 3, after one injection of ACTHJ24 1 mg i.m.; day 8, after five injections of ACTH1.24 1 mg i.m.; day 22, sixteen days after the
last injection of ACTH124. Data are expressed as median (range).
Apo is apolipoprotein.P < 0.05 as compared to day 1
METHODS
Patients
Patients in this study were recruited from the Dialysis Depart-
ment, National University Hospital, Reykjavik, Iceland. Eight
patients on chronic hemodialysis were included in the study; these
four males and four females had a median age of 69 years (range
50 to 75 years). The cause of renal failure was chronic glomeru-
lonephritis (N = 2), chronic interstitial nephritis (N = 2),
polycystic kidney disease (N = 2), and nephrosclerosis (N = 2).
Patients with liver disease or endocrine disorders other than those
accompanying renal failure, and patients treated with steroids or
lipid-lowering drugs were excluded. All were treated with polysul-
fone dialyzers and bicarbonate dialysate, four to five hours three
times a week. In seven patients, dialysis-associated anticoagula-
tion was achieved by unfractionated heparin. One warfarin-
treated patient managed without additional anticoagulation. The
median duration of dialysis was 18 months (range 4 to 108
months).
As shown by the median baseline values in Table 1, the patients
represented the lipoprotein pattern usually observed in uremia.
Their serum triglyceride concentration was slightly increased,
ranging from normal to moderately increased. Due to a low HDL
cholesterol concentration, the LDL cholesterol/HDL cholesterol
ratio was unfavorable.
Procedures
The following protocol, outlined in Figure 1, was carried out
after the consent of the local ethics committee:
Day 1. At baseline, blood samples (see below) were collected
before a hemodialysis session that was performed in the morning.
Directly after the treatment, Synacthen Depot, a synthetic N-
terminal fragment (1-24) of ACTH (Ciba-Geigy, Base!, Switzer-
land) was injected intramuscularly at a dose of 1 mg.
Day 3. The same procedure was repeated.
Days 4 5 and 6. Synacthen Depot I mg was injected intramus-
cularly, always at noon.
Day 8. Blood samples were collected before dialysis.
Day 22. Blood samples were collected before dialysis.
Thus, the blood samples, intended for estimation of treatment
effect (days 3 and 8), on both occasions were collected two days
after the latest injection. On days 1, 8 and 22, midweek dialysis
sessions were performed.
Blood samples
Blood samples were collected after a 12 hour fast for analysis of
serum concentrations of total cholesterol, HDL cholesterol, trig-
lycerides, apolipoprotein (apo) Al, apo B, total and nonapo
B-associated apos CIII and E, Lp(a), cortisol, and at baseline,
plasma concentration of ACTH. Then heparin (Lövens, Ballerup,
Denmark) was injected at a of dose of 50 lU/kg body wt. After
exactly 15 minutes, a sample was collected in a chilled EDTA-
containing test tube for analysis of plasma activities of LPL and
hepatic lipase (HL). This sample was placed directly on ice and
centrifuged within an hour. All samples were stored frozen at
—70°C for analysis in one series.
Analyses
Total cholesterol and triglyceride concentrations were analyzed
with enzymatic methods (Boehringer-Mannheim, Mannheim,
Germany). HDL cholesterol concentrations were analyzed after
precipitation of LDL and vely low density lipoprotein (VLDL)
cholesterol with dextran sulphate and magnesium chloride. LDL
cholesterol concentrations were calculated by the Friedewald
formula in seven patients, manifesting serum triglyceride concen-
trations below 4.0 mmol/liter [15].
Lp(a) concentrations were measured with a radioimmunoassay
(Mercodia, Uppsala, Sweden) and apo Al as well as apo B
concentrations were measured with immunoturbidimetry with
reagents from Roche (Base!, Switzerland). Apo CIII and apo E
concentrations, both total and those not associated with apo B,
were analyzed with electroimmunodiffusion at Institut Pasteur
(Lille, France) [16]. Concentrations of the apo B-associated apos
CIII and E were obtained by subtracting those not associated with
apo B from the total concentrations. Intra-assay variation of Lp(a)
and apolipoprotein analyses was < 3%.
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Fig. 1. Percentage changes in study variables on days 3, 8 and 22 as compared to baseline. Arrows indicate injections of ACTH124 I mg i.m.
Abbreviations are: Apo B, apolipoprotein B; apo AT; apolipoprotein AT; apo Gill-B, apolipoprotein CIII associated with apolipoprotein B; apo
CIII-nonB, apolipoprotein CIII not associated with apolipoprotein B; chol, cholesterol; HDL, high density lipoprotein; HL, hepatic lipase; LDL, low
density lipoprotein; LPL, lipoprotein lipase; Lp(a), lipoprotein(a); TG, triglycerides. Symbols in A are: (0) apo B; (LI) LDL chol; (A) LDL/HDL; (3)
chol. Symbols in B are: (LII) apo Al; (0) HDL chol; (A) HL; (0) apo CIIl-nonB. Symbol in C is: (0) Lp(a). Symbols in D are: (LI) LPL; (0) apo CIII-B;(A) TG.
ACTH concentrations were measured with an immunoradio-
metric assay (Eurodiagnostics BY, Milab, MalmO, Sweden). This
assay does not detect ACTH124, which is why plasma ACTH
concentrations were analyzed only at baseline. Cortisol concen-
trations were measured by a radioimmunoassay with reagents
from Farmos Diagnostica (Turkku, Finland).
Lipase activities were analyzed with direct and selective meth-
ods using sonicated [3H]-trioleoylglycerol emulsions, stabilized by
phosphatidyl choline, as substrates [17]. As LPL, but not HL,
rapidly hydrolyzes a substrate emulsion to which albumin has
been added after sonication, specific measurements were achieved
at pH 8.0, 0.15 M NaCI, and in the presence of serum. HL activities
were selectively determined, using a substrate sonicated in the
presence of albumin by assay at pH 9.0 and 0.5 M NaCI.
Statistical methods
Differences in the variance of study variables between test
occasions were assessed by the Friedman test. In case of a
significant Friedman test, the differences between the variable at
baseline and at the other test occasions were estimated by the
Wilcoxon rank sum test. Correlations between variables were
assessed by the Spearman rank correlation test. Data are ex-
pressed as median (range).
RESULTS
All study participants were clinically stable during the study
period and no adverse effects were observed. The results are
shown in Table 1 and Figure 1. A decrease in serum Lp(a)
concentrations was the only significant change observed after one
injection of Synacthen. However, after five injections, a further
decrease, amounting to 65%, had occurred in the median serum
Lp(a) concentration and the median serum concentrations of total
cholesterol, LDL cholesterol and apo B as well as the LDL
cholesterol/HDL cholesterol ratio were significantly decreased by
15 to 30%. Median serum concentrations of total and nonapo
B-associated apo CIII were also significantly increased but not
that of apo B-associated apo CIII. All these variables returned to
near baseline levels sixteen days after the last injection. There
were no significant changes in serum concentrations of triglycer-
ides, HDL cholesterol, apo A! and apo E. The same applied to
post-heparin plasma lipase activities.
The relationships between variables agreed with the literature.
There was a significant direct correlation between serum concen-
trations of apo B and those of total cholesterol (r = 0.92, P <
0.0001) and LDL cholesterol (r = 0.84, P < 0.0001). Serum
concentrations of Lp(a) correlated significantly with those of total
cholesterol (r = 0,31, P < 0.05), LDL cholesterol (r = 0.37, P <
A
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0.05) and apo B (r = 0.44, P < 0.05), but not with those of
triglycerides. There were significant correlations between serum
triglyceride concentrations and serum concentrations of HDL
cholesterol (r =
—0.56, P < 0.01), apo Al (r = —0.34, P < 0.05)
and apo B-associated apo CIII (r = 0.81, P < 0.0001) as well as
post-heparin plasma activities of LPL (r =
—0.73, P < 0.0001) and
HL (r 0.37, P < 0.05). Serum concentrations of HDL choles-
terol correlated significantly with those of apo Al (r = 0.90, P <
0.0001), nonapo B-associated apo CIII (r = 0.49, P < 0.01) and
nonapo B-associated apo E (r = 0.41, P < 0.05), as well as
post-heparin plasma activities of LPL (r = 0.40, P < 0.5) and HL
(r =
—0.38, P < 0.05). The relationships between the data of each
test occasion were analyzed separately, with results consistent with
those above.
There were significant direct correlations between the relative
changes in serum concentrations of total apo CIII and total
cholesterol (r = 0.91, P < 0.05) and LDL cholesterol (r = 1.0,P <
0.05). However, there were no significant correlations between the
absolute changes in the same variables. The absolute changes in
serum concentrations of Lp(a) correlated directly with baseline
concentrations (r = 0.92, P < 0.05) whereas the relative changes
did not. There were no significant correlations between baseline
and absolute or relative changes in serum concentrations of total
cholesterol, LDL cholesterol, apo B or total apo CIII.
At baseline, the median plasma ACTH concentration (18
pmol/liter (8 to 36 pmol/Iiter)] was roughly twice as high as the
upper reference level. Plasma ACTH concentrations at baseline
neither correlated with baseline levels nor with relative changes of
any of the study variables. The median serum cortisol concentra-
tion was 747 nmol/liter (393 to 857 nmol/liter) at baseline, rising
to 1453 nmol/liter (825 to 2000 nmol/liter) after one ACTH
injection and 1321 nmol/liter (501 to 1896 nmol/liter) after five
injections and again returning to baseline levels, 600 nmol/liter
(393 to 1002 nmol/liter). Baseline serum cortisol concentrations
were within the normal range. Serum cortisol concentrations did
not correlate with other study variables.
DISCUSSION
The aim of the present study was to investigate the effect of
short-term ACTH treatment on lipid metabolism in uremic
patients. After five injections of ACTH, serum concentrations of
total cholesterol, LDL cholesterol, apo B and Lp(a) decreased by
15 to 65%, a response similar to that previously found in healthy
individuals and steroid-treated patients [11, 12]. In contrast to
these groups, there was apparently no effect on triglyceride and
HDL metabolism in the uremic patients, in spite of increased
serum apo CIII concentrations.
It has generally been assumed that, apart from stimulating
cholesterol uptake in the adrenal gland, ACTH exerts its effect on
lipoprotein metabolism through corticosteroids. However, we
have recently shown that administration of ACTH induces
changes in the serum lipoprotein pattern that arc partly different
from those observed after steroid treatment [ii]. In healthy
individuals, short-term ACTH treatment resulted in a decrease in
serum concentrations of LDL cholesterol, VLDL cholesterol,
VLDL triglycerides as well as Lp(a), and an increase in serum
HDL cholesterol concentrations [11]. These changes in serum
concentrations of HDL cholesterol and Lp(a), also observed after
short-term treatment with dexamethasone, were probably, at least
partly, steroid-mediated. However, as the decrease in LDL and
VLDL lipids could not be attributed to steroidal influence, the
findings were assumed to represent a direct ACTH effect, most
easily explained by an increased receptor-mediated uptake of apo
B-containing lipoproteins. This hypothesis was supported by in
vitro experiments showing that ACTH, added to the culture media
of HepG2 cells, stimulated the LDL receptor activity [11]. The
reduction in HL activity observed after administration of ACTH
but not that of dexamethasone also seemed to be the result of a
direct hepatic effect; the addition of ACTH to the culture media
of HepG2 cells led to a reduced HL secretion (Berg et al,
unpublished results). In long-term steroid-treated patients with
iatrogenic ACTH deficiency, short-term ACTH treatment in-
duced the same changes as in healthy individuals, except for a
more marked reduction in serum triglyceride concentrations and
an increase in the previously low LPL activities [12]. The lipid-
lowering effect of ACTH has been shown to last for at least eight
months (Berg et al, unpublished observations). The future impli-
cations of the above findings most obviously include treatment
possibilities for steroid-induced hyperlipidemia and perhaps also
for other types of hyperlipidemia. The more extended application
of ACTH treatment depends on whether it will be possible to
separate the hepatic effects from the adrenal actions, possibly
residing in different peptide fragments.
The lipoprotein profile of uremic patients, characterized by
hypertriglyceridemia, an elevated LDL/HDL ratio, and increased
Lp(a) concentration, clearly constitutes a cardiovascular risk
pattern. There is evidence that fibrates [18] as well as statins [19]
have favorable effects on this lipoprotein pattern without an
unreasonably high incidence of side effects. However, neither of
these drug types influences Lp(a) concentration. The present
study confirmed the lowering effect of ACTH on the LDL/HDL
ratio and the even more marked lowering effect on serum Lp(a)
concentration in patients on hemodialysis. However, the hypertri-
glyceridemia, which may add to the cardiovascular risk pattern in
uremic patients, did not respond to ACTH. The Lp(a)-lowering
effect, in particular, renders a possible future ACTH-derived
medication an attractive treatment option for uremic patients.
No persistent or significant changes were noted regarding
triglyceride metabolism, an observation that differs from previous
studies. It is possible that the LPL-lowering mechanisms, specific
for renal failure, were resistant to the influence of ACTH. The
patients studied were on hemodialysis, receiving unfractionated
heparin three times a week. Conceivably, the tissue depots of
LPL, depleted by heparin [20], did not have the time for an
ACTH-induced recovery during the present short-term experi-
ment. It is also noteworthy that post-heparin plasma HL activities
did not decrease significantly, in contrast to the HL response to
ACTH in healthy controls and steroid-treated patients.
Apo CIII is synthesized by the liver. As a structural part of
triglyceride-rich lipoproteins, its main function is believed to be
the inhibition of premature hepatic uptake of these lipoproteins
[21]. During the lipolytic process, the excess apo CIII is trans-
ported from the partially degraded triglyceride-rich lipoproteins
to HDL. In fact, most of the circulating apo CIII is carried by
HDL. However, slow removal of triglyceride-rich lipoproteins is
accompanied by an increase in the apo CIII fraction that is
associated with apo B. The present observation of significantly
increased serum apo CIII concentrations, in spite of unchanged
serum triglyceride concentrations, is of theoretical interest. This is
probably caused by increased hepatic synthesis of apo CIII. If it
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had been caused by the accumulation of triglyceride-rich lipopro-
teins, this should have been reflected by increased serum concen-
trations of triglycerides and apo B-associated apo CIII. It can be
speculated that the excess of hepatic apo CIII was channeled
towards the nascent HDL or, less likely, into the circulation.
Confined to the nonapo B-associated fraction, the excess apo CIII
did not seem to disturb triglyceride or HDL metabolism, such as
by inhibiting LPL activity [22] or by preventing the uptake of
partially metabolized triglyceride-rich particles [21]. It is also
possible that the increased availability of apo CIII did indeed
inhibit the removal of triglyceride-rich lipoproteins and thereby
prevented the expected decrease in serum triglyceride concentra-
tion. The effect of ACTH on apo CIII concentration in healthy
individuals is not documented. Further studies on the effects of
ACFH on triglyceride metabolism in healthy as well as in uremic
individuals are called for; possibly ACTH treatment can function
as a model for studies on the effect of increased hepatic apo CIII
synthesis.
In addition to the resistance of triglyceride metabolism, there
was another difference between the uremic response to ACTH
treatment as compared to previously studied groups. In the
uremic patients, only serum concentrations of Lp(a) were signif-
icantly influenced after the first injection, indicating a more
sluggish response or a need for a higher dose than in nonuremic
individuals. This can probably be explained by a general but
compensated resistance to the effects of ACTH in uremia,
reflected by increased ACTH concentrations in combination with
normal diurnal variation in cortisol concentrations [13, 14]. The
high plasma ACTH concentrations found in our patients at
baseline support this concept.
From previous studies, we learned that the lipoprotein metab-
olism of individuals who were either normal or deficient regarding
ACTH responded rapidly to short-term ACTH treatment. The
present study results demonstrate that ACTH resistant patients
also respond, though comparatively slowly. The uremic patients
exhibited significant decreases in serum Lp(a) concentrations and
LDL cholesterol/HDL cholesterol ratios in response to short-term
ACTH treatment, changes that improve their cardiovascular risk
profile. Interestingly, serum triglyceride concentrations mani-
fested no significant change.
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APPENDIX
Abbreviations are: Apo B, apolipoprotein B; apo Al; apolipoprotein AT;
apo CuT-B, apolipoprotein CIII associated with apolipoprotein B; apo
CTIT-nonB, apolipoprotein CIII not associated with apolipoprotein B;
HDL, high density lipoprotein; HL, hepatic lipase; LDL, low density
lipoprotein; LPL, lipoprotein lipase; Lp(a), lipoprotein(a); TG, triglycer-
ides.
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